The minimally invasive system is made up of two pacemakers that send signals back and forth to one another. One pacemaker is placed on the patient's right ventricle, and the other is placed on the patient's right atrium. 

The FDA has categorized this as a Class I recall, meaning the use of these devices could cause “serious injuries or death.”

There is a risk of the devices sending a reduced amount of energy to the heart during defibrillation. More than 7,000 devices are being recalled due to this issue.

Researchers tracked data from nearly 7,000 TAVR patients for two years, focusing on all-cause mortality and heart failure hospitalizations.

The new-look devices are soft, flexible, transparent and roughly the size of a postage stamp.

Targeting immune cells that play a key role in the development of atrial fibrillation could give cardiologists a new way to treat the disease.

Lead Edge Capital is a well-known tech investor that has previously worked with such groups as Spotify, Duo Security and Toast.